Serum Total Bilirubin Concentration Is Inversely Correlated with Framingham Risk Score in Koreans

Archives of Medical Research

Volumn 43, Issue 4, 2012, Pages 288-293

  Kim, Kwang Min ^a   Kim, Bom Taeck ^a   Park, Sat Byul ^a   Cho, Doo Yeoun ^a   Je, Sang Hyeon ^a   Kim, Kyu Nam ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Framingham risk score; Oxidative stress; Total bilirubin

Indexed keywords

BILIRUBIN; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; LIVER ENZYME; URIC ACID;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; FEMALE; FRAMINGHAM RISK SCORE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NORTH KOREA; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; URIC ACID BLOOD LEVEL;

EID: 84864104998     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.05.003     Document Type: Article

References (38)

1. Mackay J., Mensah G.A., Mendis S., et al. The atlas of heart disease and stroke 2004, 58. World Health Organization, World Health Organization, Geneva, 46-49.
2. Roberts C.K., Barnard R.J., Sindhu R.K., et al. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 2006, 55:928-934.
3. Bo S., Gambino R., Durazzo M., et al. Associations between gamma-glutamyltransferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress. World J Gastroenterol 2005, 11:7109-7117.
4. Tomaro M.L., Bartle A.M. Bilirubin: its role in cytoprotection against oxidative stress. Int J Biochem Cell Biol 2002, 34:216-220.
5. Baranano D.E., Rao M., Ferris C.D., et al. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2005, 99:16093-16098.
6. Basiglio C.L., Arriaga S.M., Pelusa F., et al. Complement activation and disease: protective effects of hyperbilirubinaemia. Clin Sci 2009, 118:99-113.
7. Cheriyath P., Gorrepati V.S., Peters I., et al. High total bilirubin as a protective factor for diabetes mellitus: an analysis of NHANES Data From 1999-2006. J Clin Med Res 2010, 2:201-206.
8. Han S.S., Na K.Y., Chae D.W., et al. High serum bilirubin is associated with the reduced risk of diabetes mellitus and diabetic nephropathy. Tohoku J Exp Med 2010, 221:133-140.
9. Chin H.J., Song Y.R., Kim H.S., et al. The bilirubin level is negatively correlated with the incidence of hypertension in normotensive Korean population. J Korean Med Sci 2009, 24:50-56.
10. Choi S.H., Yun K.E., Choi H.J. Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutr Metab Cardiovasc Dis 2011 Jun 22, [Epub ahead of print].
11. Jo J., Yun J.E., Lee H., et al. Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population. Endocrine 2011, 39:182-189.
12. Schwertner H.A., Jackson W.G., Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994, 40:18-23.
13. Breimer L.H., Wannamethee G., Ebrahim S., et al. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995, 41:1504-1508.
14. Erdogan D., Gullu H., Yildirim E., et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 2006, 184:431-437.
15. Perlstein T.S., Pande R.L., Beckman J.A., et al. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999-2004. Arterioscler Thromb Vasc Biol 2008, 28:166-172.
16. Ganotakis E.S., Vrentzos G.E., Gazi I.F., et al. Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. In Vivo 2007, 21:685-694.
17. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
18. D'Agostino R.B., Russell M.W., Huse D.M., et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000, 139:272-281.
19. Greenfield T.K. Ways of measuring drinking patterns and the difference they make: experience with graduated frequencies. J Subst Abuse 2000, 12:33-49.
20. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002, 106:3143-3421.
21. Stocker R., Yamamoto Y., McDonagh A.F., et al. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
22. Liu Y., Li P., Lu J., et al. Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J Immunol 2008, 181:1887-1897.
23. Kalousova M., Novotny L., Zima T., et al. Decreased levels of advanced glycation end-products in patients with Gilbert syndrome. Cell Mol Biol 2005, 51:387-392.
24. Kumar A., Pant P., Basu S., et al. Oxidative stress in neonatal hyperbilirubinemia. J Trop Pediatr 2007, 53:69-71.
25. Kapitulnik J., Maines M.D. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci 2009, 30:129-137.
26. Lin L.Y., Kuo H.K., Hwang J.J., et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009, 203:563-568.
27. Wu Y., Li M., Xu M., et al. Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes 2011, 3:217-224.
28. Troughton J.A., Woodside J.V., Young I.S., et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 2007, 14:79-84.
29. Vitek L., Jirsa M., Brodanovà M., et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002, 160:449-456.
30. Schwertner H.A., Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008, 198:1-11.
31. Bosma P.J., van der Meer I.M., Bakker C.T., et al. UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin Chem 2003, 49:1180-1181.
32. Lin J.P., Vitek L., Schwertner H.A. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010, 56:1535-1543.
33. Ekblom K., Marklund S.L., Jansson J.H., et al. Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting. Circ Cardiovasc Genet 2010, 3:340-347.
34. Gajdos V., Petit F.M., Perret C., et al. Further evidence that the UGT1A1*28 allele is not associated with coronary heart disease: the ECTIM Study. Clin Chem 2006, 52:2313-2314.
35. Lin J.P., O'Donnell C.J., Schwaiger J.P., et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006, 114:1476-1481.
36. D'Agostino R.B., Grundy S., Sullivan L.M., et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic group investigation. J Am Med Assoc 2001, 286:180-187.
37. Barzi F., Patel A., Gu D., et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 2007, 61:115-121.
38. Neuzil J., Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 1994, 269:16712-16719.